logo-loader

Oncimmune has “substantially reduced” commercial risk for EarlyCDT cancer test, says broker

Published: 15:06 22 Nov 2019 GMT

Oncimmune - Oncimmune has “substantially reduced” commercial risk for EarlyCDT cancer test, says broker
EarlyCDT is a test that aims to detect lung cancer at as early a stage as possible

Oncimmune Holdings PLC (LON:ONC) has “substantially reduced” the commercial launch risk for its EarlyCDT lung cancer test through a series of supply and licence deals, according to analysts at finnCap.

In a note initiating the biotech firm with a price target of 150p, the broker said the company’s business model reduced execution risk through supply and licence deals in the US and China, distribution agreements in 23 additional markets and “a diversifying pipeline of revenues”.

READ: Oncimmune Holdings draws down final tranche of IPF facility

As a result, they expected “early evidence of the revenue ramp” in the current year, predicting £400,000 in revenues for the first half of the 2020 financial year and £800,000 for the second half.

finnCap also expects Oncimmune to be cash flow positive by 2024, while its current cash balance, which provides funds until 2022, would provide “the time to deliver further meaningful valuation points”.

In late-afternoon trading on Friday, Oncimmune shares were 1% higher at 51p, a 66% discount to finnCap’s target price.

Oncimmune's strategic pivot aims for robust growth in 2024

Oncimmune Holdings PLC (AIM:ONC) CEO Martin Gouldstone joins Proactive's Stephen Gunnion with highlights of the company's 2023 performance, which included its strategic decision to focus on its ImmunoINSIGHTS platform. A significant development was the sale of its early lung cancer detection...

3 weeks, 1 day ago